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474 The Journal of Thoracic and Cardbjective: To establish the safety and efficacy of endovascular repair of thoraco-
bdominal aortic aneurysms.
ethods: Between May 2004 and February 2006, patients with thoracoabdominal
neurysms considered high risk for conventional surgery were enrolled in a pros-
ective trial to evaluate a novel endovascular grafting system. Devices were custom
esigned for each patient using high-resolution computed tomography. Patient data
ncluded mortality, morbidity, procedural details, and surrogate end points for
ndovascular repair. These were collected at hospital discharge and at 1, 6, and 12
onths.
esults: Seventy-three patients underwent endovascular repair of thoracoabdominal
ortic aneurysms for type I, II, or III (n  28), or for type IV (n  45) thoracoab-
ominal aneurysms. Mean aneurysm size was 7.1 cm (range 4.5–11.3 cm). General
nesthesia was used in 47% of patients and regional anesthesia in 53%. There were
o conversions to open surgery nor ruptures post-treatment. Technical success was
chieved in 93% of patients (68/73). Thirty-day mortality was 5.5% (4/73). Major
erioperative complications occurred in 11 (14%) patients and included paraplegia
2.7%, 2/73), new onset of dialysis (1.4%, 1/73), prolonged ventilator support
6.8%, 5/73), myocardial infarction (5.5%, 4/73), and minor hemorrhagic stroke
1.4%; 1/72). A majority of patients had no complications. Mean length of stay was
.6 days. At follow-up, 6 deaths had occurred. There were no instances of stent
igration nor aneurysmal growth.
onclusions: Endovascular repair of aortic aneurysms involving the visceral seg-
ent in nonsurgical candidates is feasible. Known complications of repair are not
liminated, but morbidity and mortality appeared low relative to the high-risk
opulation studied. Further refinement of device design, delivery technique, and
atient selection is ongoing. Assessment of durability will require longer follow-up.
tandard surgical approach to the treatment of thoracoabdominal aneurysms
requires a demanding operation. Surgical outcomes are complicated by the
presence of multiple comorbid conditions in these patients. Use of improved
echniques has lowered the risk of complications and testifies to the effectiveness of
reatment evolution and surgical experience in improving outcomes. However, risk
or morbidity and mortality in this challenging patient population is still substantial.
arge single-center experiences have reported mortality ranging from 7.4% to
7%.1-6 A recently published population-based study reported 20% perioperative
ortality and only 69% survival at 12 months.7 Cardiac, neurologic, respiratory, and
enal complications limit the number of patients eligible for surgery. All of these
actors have encouraged the development of an alternative approach.
Endovascular repairs of straightforward infrarenal and thoracic aortic aneurysms
ave been favorably compared with surgical controls.E1-E4 The application of this
iovascular Surgery ● June 2007
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A
CDechnology to segments of the aorta with visceral or bra-
hiocephalic branches has required modifications of devices
nd procedures. Fenestrated devices have been developed to
reat juxtarenal aneurysms, and the use of branched devices
o treat aneurysms of the visceral and arch segments has
een reported.8-13 We have explored a broadened indication
or the use of endovascular procedures to treat aneurysms of
he visceral segment. This article describes the techniques
nd reports the results of branched stent grafts to treat
horacoabdominal aortic aneurysms in select high-risk
atients.
aterials and Methods
atients
rom May 2004 through February 2006, 73 patients with thora-
oabdominal aortic aneurysms were evaluated in a prospective,
onrandomized fashion as part of a physician investigator–
ponsored device exemption study, and the patients were treated
ith custom-designed branched endovascular devices. Written in-
ormed consent was obtained from all patients after full discussion
f the purposes, risks, potential benefits, alternatives, need for
ollow-up studies, and investigational nature of the procedure. The
tudy was approved by the Institutional Review Board. All patients
ere evaluated by surgeons who offer open and endovascular
reatment alternatives. Preoperative assessment included func-
ional stress tests and selective coronary angiography based on
esults, transthoracic echocardiography, pulmonary function test-
ng, routine blood work, and physical exam.
Quantification of patients as poor candidates for conventional
urgery is challenging, even for surgeons with extensive experi-
nce. The determination was made largely based upon the patient’s
ge, aneurysm morphology, and comorbid factors present.1-7 All
atients enrolled were considered high risk for open surgery after
urgeons’ assessment of all of these factors. Associated comor-
idities are delineated in Table 1.
High-resolution computed tomography (CT) scans were ac-
uired to evaluate the entire aorta and assessed on a 3-D imaging
ork station (Aquarius WS, Terarecon Inc, Mateo, Calif). Only
atients treated for aneurysms that involved visceral aortic
ranches are reported.
evice Construct
he Zenith endograft (Cook Inc, Bloomington, Ind), previously
tudied for treatment of infrarenal abdominal aortic aneurysms,
uxtarenal abdominal aortic aneurysms, and thoracic aneurysms,
ormed the basis of this device.E2,E3,8,10 Branches for the visceral
egment were added to a tubular component that transcended the
isceral segment in a manner similar to prior reports11,12 (Figure
). Two types of branches were constructed depending upon the
istance of the visceral ostia from the presumed location of the aortic
Abbreviations and Acronyms
CT computed tomographyrosthesis. The first involved a fenestration circumferentially rein- t
The Journal of Thoracicorced with a nitinol ring (reinforced fenestrated design). This was
ated with a balloon-expandable stent graft partially extending
ithin the aortic stent-graft lumen. The aortic segment of the
alloon-expandable stent graft was then flared using sequentially
arger balloons (12-mm, then a compliant 32-mm balloon) to abut
ABLE 1. Patient and procedural characteristics
atient variables n  73 (%)
Demographic
Age (y, mean  SD) 75 8
Male (no.) 56 (76)
Aneurysm characteristics
Size (mm, mean  SD) 70.7 15.1
Type I/II/III 77.3 16.8
Type IV 66.5 12.5
Distribution (no.)
Type I/II/III 28 (38.4)
Type IV 45 (61.7)
Comorbidities (no.)
HTN 49 (67)
DM 13 (18)
CAD 44 (60)
LVEF  35% 19 (26)
CHF 21 (29)
h/o MI 25 (34)
h/o coronary revascularization 18 CABG, 11 PCI (40)
AICD 11 (15)
COPD 34 (47)
Home O2 requirement 14 (19)
Baseline creatinine  1.5 mg/dL 19 (26)
Serum creatinine (mg/dL, mean  SD) 1.4 0.9
Cerebrovascular disease 8 (11)
Prior aortic surgery 21 (29)
erioperative details n 73 (%)
Technical success (no.) 68 (93)
Angiographic evidence of aneurysm
exclusion
73 (100)
Complete branch revascularization 69 (95)
Anesthesia (no.)
Regional 39 (53)
General 34 (47)
Time (min, mean  SD)
Total 320 106
Fluoroscopy 73.9 38.3
Contrast volume (mL, mean  SD) 210 99
Access (no.)
Common iliac conduit 7 (10)
Length of stay (days, mean  SD)
ICU 3.2  5.2
Total 8.6 9.8
TN, Hypertension; DM, diabetes mellitus; CAD, coronary artery disease;
VEF, left ventricular ejection fraction; CHF, chronic heart failure; MI,
yocardial infarction; AICD, automated internal cardiac defibrillator;
OPD, chronic obstructive pulmonary disease requiring inhaler therapy;
ABG, coronary artery bypass grafting; PCI, percutaneous coronary inter-
ention; ICU, intensive care unit.he stent graft to the aortic graft, achieving a seal around the nitinol
and Cardiovascular Surgery ● Volume 133, Number 6 1475
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A
CDing. The second branch type, termed a directional branch, con-
isted of an 8-mm polyester graft sewn to the aortic prosthesis
bove the target vessel. The branch was wrapped in a helical
ashion external to the aortic prosthesis, oriented in either an
ntegrade or retrograde fashion, and terminated proximal to the
arget vessel. Directional branches provide long regions (2 cm) of
verlap, allowing for the mating of a self-expanding stent graft
Fluency, Bard Inc, Tempe, Ariz) sized to the visceral vessel. A
iven device may have incorporated both types of branches based
n the patient’s anatomy.
evice Design
ll devices were modular in design. The proximal and distal extent
f aneurysmal disease, fixation and sealing zones, luminal diam-
ters, and precise relationship between the visceral branches were
etermined using 3-D imaging. Sealing regions were oversized by
0% to 20%. Device lengths were calculated from centerline of
ow reconstructions with the objective of covering the minimum
mount of aorta necessary while preserving internal iliac circula-
ion. Additional internal iliac branches were used when needed.12
rocedures
rocedures included bilateral femoral artery exposure, anticoagu-
ation to maintain activated clotting times greater than 300 sec-
nds, and selective exposure of brachial access sites. The primary
evice was delivered over a stiff wire that terminated in the
scending aorta. Each branch component was introduced through
he contralateral femoral or brachial artery.
Longitudinal positioning of the aortic component was assisted by
mall injections of contrast above the celiac artery or by selective
ccess of branch arteries to mark their positions. The device was then
nsheathed. A posterior tethering wire partially constrained the graft,
llowing fine positioning adjustments during selective cannulation of
ach visceral branch from within the aortic prosthesis.
Antegrade helical branches were selectively accessed with a pre-
oaded wire and catheter. Retrograde helical branches and reinforced
enestrations were catheterized from femoral access points. Curved 7F
r 8F sheaths were placed into respective branches.
After access into each visceral vessel through the intended
ranch, the aortic component was completely expanded by re-
oval of the posterior tethering wire. Release of the proximal e
476 The Journal of Thoracic and Cardiovascular Surgery ● Junxation component allowed barbs to engage within the aortic wall.
alloon-expandable stent grafts (reinforced fenestrated branches)
hat were 17 to 38 mm in length (Jomed, Abbott Labs, Abbott
ark, Ill) or self-expanding stent grafts (helical branches) that were
0 mm in length (Fluency, Bard, Tempe, Ariz) were delivered.
alloon-expandable stent grafts were flared. The aortic delivery
ystem was removed and proximal thoracic, distal bifurcated iliac,
r internal iliac components were added as required.
erioperative Patient Management
egional anesthesia was preferentially used in patients with signifi-
ant comorbid pulmonary disease (Table 1). Patients were usually
ollowed in an intensive care unit for a minimum of 12 hours (n 
3). Spinal drainage was selectively employed depending on extent of
ortic coverage (type I, II, and III aneurysms) or in the setting of prior
ortic repair (n  37). Drainage was continued for 72 hours or until
T scan confirmed aneurysm exclusion. Hydration and N-acetyl
ysteine were administered before and after procedures for patients
ith chronic renal insufficiency. Other than aspirin, no anticoagula-
ion was prescribed as a result of the aortic procedure.
ollow-up
maging and clinical evaluations occurred at 1, 6, and 12 months
ostoperatively and annually thereafter. Mortality data were avail-
ble for all patients, and 92% of patients were compliant with
linical and imaging follow-up. Studies included serum creatinine
nd blood urea nitrogen, CT, visceral duplex ultrasonography, and
lain chest and abdominal radiographs. Image evaluation was
onducted on a work station using 3-D techniques (Figure 2).
utcome Definitions, Database, and
tatistical Management
he main objectives of therapy were to exclude the aneurysm and
evascularize all associated branches during a single procedure.
echnical success was defined by prosthesis implantation with
atency of all intended branches, absence of angiographic evi-
ence of type I or III endoleaks, and survival through 24 hours.
ther end points included acute and late mortality; neurologic,
ardiovascular, respiratory, and renal complications (Appendix E1);
nd radiographic outcomes consistent with reporting standards for
Figure 1. Main body device tethered to delivery
system, demonstrating branch fenestrations for
the (A) celiac and superior mesenteric arteries
and (B) helical branch in antegrade orientation
for the celiac artery (posterior view) and a rein-
forced fenestration for the left renal artery. Also
note the posterior tethering sutures in (B).ndovascularE6 aneurysm repair.
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A
CDData were entered into an Oracle database. Mortality was assessed
sing life table analyses. Branch patency during follow-up studies was
efined by contrast CT or duplex ultrasound, and device migration
as defined according to recent modifications.14
esults
echnical Success
echnical success was achieved in 68 (93%) patients. There
ere no conversions to open repair. Five technical failures
igure 2. Completion CT scans post procedure. (A) Arterial con-
rast phase reconstruction of a type II thoracoabdominal aneu-
ysm after repair with a 4-branch reinforced fenestrated device.
B) Noncontrast images reconstructed to demonstrate the in vivo
ppearance of a stent graft used to treat a type III thoracoab-
ominal aneurysm using composite device design with a helical
eliac branch (purple arrows) and 3 reinforced fenestrated
ranches (green arrows).ncluded a single death within 24 hours, and 4 patients in a
The Journal of Thoracichom we were unable to access a single branch artery.
hree of these 4 patients underwent a second procedure to
ain access into the failed branch during the same hospital-
zation in an effort to limit the initial contrast dose. A celiac
rtery was successfully accessed and stent grafted, and none
f 3 renal arteries were salvaged.
ortality
robability of freedom from all-cause mortality (94%, 85%,
nd 81%) and aneurysm-related mortality (94%, 89%, and
9%) at 1, 6, and 12 months, respectively, is shown in
igure 3.
Acute mortality. Four patients died within 30 days, 2
rior to discharge. One died from a myocardial infarction
ithin 24 hours of completing the procedure (which in-
luded a common iliac endarterectomy and iliofemoral by-
ass for device delivery), and the other died on day 7 from
orsening biventricular failure. The other 2 acute mortali-
ies followed discharge: 1 from mesenteric ischemia and 1
rom renal failure.
Late mortality. Six patients died more than 30 days after
urgery. Two patients expired at extended care facilities
rom complications related to spinal cord injuries. One died
t an outside hospital due to an upper gastrointestinal bleed
days following embolization of a type II endoleak from
he inferior mesenteric artery. A fourth late death resulted
rom sepsis 6 months after the procedure. The fifth patient
ied on day 167 from an acute myocardial infarction doc-
mented by autopsy, which also provided the opportunity
or device explantation and analysis. And a sixth death
ccurred on postoperative day 312 as a result of cardiac
rrhythmia and renal failure.
orbidity
hirty-seven (52%) patients had no complications and were
ischarged after a mean of 4.9  3.0 days. Death or major
omplications occurred in 15 patients (Table E1).
Neurologic complications. One patient had a minor
emorrhagic stroke from which he recovered during hospi-
alization. Two patients had spinal cord injury: one devel-
ped paraplegia and the other paraparesis. Both were de-
ayed (3 days postprocedure), and both patients ultimately
ied at extended-care facilities. These patients had compro-
ised internal iliac perfusion before the endovascular re-
airs, and both had prophylactic drainage of cerebrospinal
uid in place at the time of the initial procedure.
Cardiovascular and respiratory complications. None of
he 10 patients with ischemia on preoperative testing had
ardiac events. Four patients had perioperative myocardial
nfarctions. Overall, 5 patients (6.8%) required prolonged
ntubation. Two of these who underwent tracheostomy are
lso the patients who had spinal cord injuries.
and Cardiovascular Surgery ● Volume 133, Number 6 1477
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1
A
CDRenal complications. Sustained elevations of serum cre-
tinine greater than 30% over baseline levels were noted in
nly 11% (6/53) of patients at 1-month follow-up. Two of
hese 6 patients had evidence of renal insufficiency preop-
ratively. One, who had paraparesis, required hemodialysis
nd eventually died. The other developed postoperative
enal artery stenosis, which was treated with repeat stenting,
nd his serum creatinine has remained stable at 3.1 mg/dL.
reatinine elevations in the other 4 patients have remained
table between 1.4 and 2.0 mg/dL at 6-month (n  2) and
2-month (n  2) follow-up.
Three patients had failed access into a single renal artery.
t follow-up, 1 of these individuals had a reduced serum
reatinine attributable to successful treatment of a tight
tenosis in his dominant kidney. The second patient had a
ise in serum creatinine, which has remained stable at 2.7
g/dL. The third refused hemodialysis and died on postop-
rative day 30.
adiographic Complications
Endoleaks and sac morphology. Overall incidence of
ndoleaks was 11% before hospital discharge. Incidence
nd categorization of endoleaks are depicted in Figure 4. All
ype I (n  3) endoleaks and all but 1 type III (n  5)
ndoleaks were treated with secondary interventions. The
ingle exception, a type III endoleak from the joint between
he visceral component and bifurcated iliac component,
esolved within 1 month. Of the 7 patients with type II
ndoleaks, 2 underwent treatment with glue embolization, 2
esolved by 1-month follow up, and the remaining 2 will be
ollowed.
There have been no known aneurysm ruptures and no
igure 3. Kaplan–Meier estimate of the survival function for
reedom from all-cause mortality (black) and aneurysm-related
blue) mortality, with pointwise 95% confidence limits.ases of sac enlargement over the follow-up period. Within n
478 The Journal of Thoracic and Cardiovascular Surgery ● Junmonths, sac size decreased in 44% of patients, and at 12
onths, 100% of eligible patients had documented sac
hrinkage of greater than 5 mm.
Secondary interventions. All secondary interventions
ere elective, and most occurred within the first month.
nterventions for type I or III endoleaks occurred either
efore discharge (n  3) or at 1-month follow-up (n  4).
dditional secondary procedures included groin complica-
ions (n  2), internal iliac artery stenosis (n  2), throm-
osed iliac graft limb (n  1), and a renal stent fracture
n  1). Freedom from secondary interventions, by life
able analysis, at 1, 6, and 12 months was 87%, 74%, and
1%, respectively.
Device integrity and branch patency. There have been
o component separations, barb fractures, or device migra-
ions. A single stent fracture was identified within a renal
tent graft (Jomed) placed into a reinforced fenestration.
his was not associated with any clinical event or endoleak
nd was treated with supplemental renal stent-graft place-
ent. All renal and visceral branch vessels patent at hospital
ischarge remain patent at late follow-up imaging (Table E1).
iscussion
hese patients were selected for endovascular versus open
epair because of serious comorbid pulmonary, cardiovas-
ular, or renal conditions, complex aortic morphology, and
high risk for aneurysm rupture. With these characteristics
n mind, the perioperative and 12-month mortality rates of
.5% and 19%, respectively, compares favorably to previ-
usly published reports.1-7
Direct comparison between historic results of open sur-
ery and the current study, however, is not accurate given
hat the patients in this series were deemed excessively
igh-risk candidates for an open repair. When compared
ith patients in other series, our patients were generally
lder; had more coronary artery disease, obstructive pulmo-
igure 4. Number and classification of endoleaks by type at each
nterval of follow up. PD, Predischarge.ary disease, and chronic renal insufficiency; and had more
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A
CDrequently undergone prior abdominal aortic repair.1-7 Fur-
hermore, these data were collected prospectively under an
ntensive clinical and imaging follow-up protocol that al-
owed for accurate charting of complications, a more reli-
ble process than retrospective review.
An alternative hybrid approach to treating these patients
ombining open surgical extra-anatomic bypass with endo-
ascular coverage of the visceral segment has been proposed
s a potentially lower-risk procedure for these difficult-to-treat
atients. In a recent review of our own experience with this
echnique, we found a 23% mortality rate and the need for
dditional open surgical procedures necessary in 6/13 pa-
ients.15 These results mirror those of others and have led us
o reserve this approach to those with no other reasonable
ptions, such as emergency cases or those with anatomy that
ould preclude branched device design (excessive tortuos-
ty or compact branch vessel origins).
The decision to treat these patients with any invasive
herapy must be weighed against the risk of aneurysm
upture. With the mean size exceeding 7 cm, it can be
stimated from the data provided by Elefteriades16 that the
ifetime risk of complications in these patients exceeds 43%.
here have been no known ruptures or evidence of aneu-
ysm growth after endovascular treatment in this series.
ven with short-term follow-up, we have documented a
ecrease in aneurysm size in many patients, lending cre-
ence to the hypothesis that such a repair reverses the
atural history of disease.
It is clear from these data that endografting has not
liminated the complications of spinal cord ischemia, renal
ysfunction, and myocardial infarction associated with the
reatment of thoracoabdominal aortic aneurysms; however,
he occurrence of such events compares favorably with
esults from open surgical treatment. The paucity of pulmo-
ary complications was particularly favorable. Ability to
erform this procedure using regional anesthesia allowed
or the treatment of patients with severe lung disease, a
actor previously shown to be predictive of poor out-
ome.1,3,17 Avoidance of aortic crossclamping, obligatory
nd organ ischemia, and excessive fluid loss also potentially
ontributed to reduce risk.
Risk of spinal cord ischemia was relatively low in this
eries (2.7% overall, 7.1% if all type IV thoracoabdominal
neurysms were excluded), despite the inability to reimplant
ntercostal arteries. This parallels the low incidence of spi-
al cord complications noted after endovascular repair of
horacic aneurysms and after extra-anatomic bypasses com-
ined with total aortic coverage.10,11,18 However, the con-
equences of this complication are devastating, exemplified
y the 2 patients in this series who ultimately died after a
omplicated postoperative course. Both patients had com-
romised internal iliac perfusion and extensive aortic cov-
rage. Increased risk of spinal cord ischemia is an unavoid- g
The Journal of Thoracicble situation when treating extensive continuous
neurysmal disease. This risk in endovascular repairs seems
o be more attributable to anatomic factors related to the
orphology of the disease than to the physiologic conse-
uences inherent to aortic clamping and open surgery.
herefore, cerebrospinal fluid drainage is employed in all
atients at anatomic risk for spinal cord injury: those with
ype I to III aneurysms and those who have had prior aortic
urgery. Similar concerns have been raised about diminishing
eft subclavian and consequently antegrade vertebral artery
ow with proximal placement of thoracic endovascular de-
ices.10,19 These observations have caused us to temper our
nthusiasm for extensive endovascular repair in the setting
f compromised pelvic or subclavian perfusion. Subse-
uently, such patients have either been turned down for a
epair, undergone initial carotid subclavian bypass proce-
ures (n  1), or had internal iliac branch device placement
n  3) to maintain antegrade perfusion to these important
ollateral vascular beds. No patients had coverage of the left
ubclavian artery without a bypass procedure.
Although the stringent definition likely overestimates
enal dysfunction in this series compared with other pub-
ished series, the conclusions are similar: patients with tho-
acoabdominal aneurysms are at risk for renal impairment.
he risk of renal failure in Godet’s6 series was 25%, with
% of the patients requiring hemodialysis. Safi’s20 focused
nalysis demonstrated a 17.5% risk of worsening renal
unction, with 15% requiring hemodialysis; half of the pa-
ients ultimately died. After endovascular repair of juxtare-
al aneurysms, the risk for needing hemodialysis was low,
ut preoperative renal dysfunction was shown to adversely
ffect survival and increase the risk for worsening renal
ysfunction.21 Similar results were suggested by the present
eries, although it was not statistically powered to demonstrate
n association. The advantage of avoiding renal ischemia with
n endovascular approach may be offset by the use of neph-
otoxic contrast agents and the risk of atheroembolization due
o device manipulation within the aneurysm.
Myocardial complications are infrequent but not elimi-
ated with an endovascular approach. Patients having open
horacoabdominal aneurysm repairs at our institution un-
ergo coronary angiography followed by revascularization,
f indicated, before aneurysm repair. However, when endo-
ascular repairs are planned, only patients with symptoms
r functional studies indicative of reversible ischemia are
valuated by cardiac catheterization. In the review of Svens-
on et al’s1 experience, an association between coronary
rtery disease and 30-day mortality was demonstrated. The
nding that later surgical series have not shown coronary
therosclerosis to be a risk for mortality may be attributable
o more aggressive screening and revascularization strate-
ies.2-5 Whether all of the patients having endovascular
and Cardiovascular Surgery ● Volume 133, Number 6 1479
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1
A
CDepair of thoracoabdominal aneurysm should undergo car-
iac catheterization remains to be seen.
echnical Issues
hese procedures are more technically demanding than
ther well-established endovascular operations. The lengthy
perative and fluoroscopic times coupled with large contrast
oses attest to their complexity (Table 1). Experience with
econstruction techniques based upon 3-D imaging systems
s critical for both patient selection and device design.
roficiency with endovascular grafting, visceral vessel dis-
ase, and the surgical skills required for conduit placement
re fundamental to success. Further problem-solving skills
re also required, such as the use of intravascular ultra-
ound, thrombolysis, and the management of distal oc-
lusive disease. Regardless of the endovascular skill
evel, severe tortuosity and concomitant occlusive dis-
ase pose serious challenges to this technique as it may to
he open technique.22
The endovascular approach and the design of this device
lace limitations on patient selection. All patients in this
eries had aneurysms; none had chronic dissections. Accu-
ate device deployment and rotational movement may be
imited by the small true lumen in patients having dissec-
ion. Therefore, these patients are currently treated with
onventional surgery at our institution. Additional anatomic
onstraints on patient selection included individuals whose
isceral arteries arose within approximately a 10-mm arc
ength of each other. Such cases have been addressed using
irectional branches or hybrid approaches combined with
xtra-anatomic bypass, but these are more challenging.
Planning, device design, and manufacturing of custom
evices create inherent delays in treatment. Therefore, pa-
ients requiring urgent or emergency repairs are relegated to
pen surgery. Potential for rupture in the intervening period
hould be considered in the overall mortality but certainly
lso occurs in patients awaiting elective open repair.
This technique will continue to undergo iterative im-
rovements with respect to patient selection, device design,
nd delivery techniques. Adequate determination of long-
erm rupture protection or device durability will require
onger follow-up of a stable design. Dissemination of this
epair technique will also require widespread availability of
dequate intraoperative imaging equipment and the mixed
kill set for proper deliver. Once these issues have been
ddressed, a more accurate comparison of open versus en-
ovascular treatment of thoracoabdominal aneurysms can
e considered.
onclusions
ndovascular repair of aortic aneurysms involving the vis-
eral segment in nonsurgical candidates is feasible. The
nown complications of thoracoabdominal aortic aneurysm
480 The Journal of Thoracic and Cardiovascular Surgery ● Junepair are not eliminated, but morbidity and mortality are
ow relative to the patient population studied. Further re-
nement of the device, technique, and patient selection is
ngoing, as is assessment of durability. Future studies may
nclude healthier patients, newer device designs, and sim-
lified delivery systems.
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iscussion
r J. Coselli (Houston, Tex). Dr Roselli, congratulations on an
utstanding presentation. You and your colleagues have boldly
uilt upon a successful track record for the endovascular treatment
f abdominal aortic aneurysms and a growing experience with the
ndovascular exclusion of juxtarenal and descending thoracic an-
urysms with this innovative approach, allowing now for treatment
f those aneurysms traversing the visceral aortic segment. This is
ndeed a significant contribution to demonstrate the feasibility of
his alternative approach to the open operation from which no
oubt many patients have benefited. It is notable that you have
een able to demonstrate that the endovascular procedure can be
arried out in many cases under regional anesthesia.
A few questions. It is a shame that this study could not have
een carried out alongside controls, particularly in view of the fact
hat the data provided regarding the Gore TAG graft is such that at
years, there was no demonstrated difference in the survival rates.
dditionally, I would like for you to comment on your postoper-
tive anticoagulation regimen for these patients, and if you could,
xplain to us why you would not recommend the use of cerebro-
pinal fluid drainage in all of your patients? Because 2 of your
pinal cord problems postoperatively were delayed, would you
ecommend the insertion of a cerebrospinal fluid catheter in such
ases? And then, regarding this particular innovative technology,
ould you comment, based upon your experience, on the require-
ents for the training and qualifications for the implementation of
uch therapy?
Again, congratulations.
Dr Eric E. Roselli (Cleveland, Ohio). Thanks, Dr Coselli. With
egard to controls, I agree, it would be nice to compare controls to
hese investigational patients. However, this is a technology that is
till in the process of evolution, and currently we are using this
electively in patients who we don’t think have a good open
urgical alternative.
Our postoperative anticoagulation regimen in these patients is
ot based at all on the procedure, although they are anticoagulated
uring the procedure. Activated clotting time is maintained above
00 throughout the procedure, but then heparin is allowed to drift
r is reversed with protamine in the operating room. Otherwise
hey receive antiplatelet therapy for concomitant coronary disease
r other comorbid indications.
Cerebrospinal fluid drainage was not used in all patients. The
atients that we used drainage for were at anatomic risk. So most
ype 1, 2, and 3 thoracoabdominal aneurysms did have drainage
atheters, and also patients with type 4 aneurysms who had had a
The Journal of Thoracicrevious aortic surgery—who we felt to be at an elevated risk. The
patients who had paraplegia did have drainage catheters in place,
nd unfortunately that wasn’t enough to prevent them from having
pinal cord ischemia. What we have learned, however, is that we
ay be able to predict the patients who are going to be at the
ighest risk based on their anatomy. Not all patients are selected
or this procedure if we believe they are at too high risk for spinal
ord injury. For example, a patient who has compromised internal
liac perfusion who is going to require coverage of their subclavian
rtery and extensive aortic coverage may not be recommended for
his procedure. If those important collateral vascular beds are
oing to be compromised from this procedure, we will find another
ay to deal with them—that is, with an internal iliac branch as an
dditional part of the device or with a preoperative carotid sub-
lavian bypass.
And then, with regard to the question of the requirements for
raining, these procedures require not only the ability to perform
omplicated large-bore vascular access techniques such as con-
uits but also other extra-anatomic bypasses such as a carotid
ubclavian bypass. Also, familiarity with complicated endovascu-
ar techniques, such as thrombolysis and embolization, and also the
now-how to deal with all of the branches of the viscera and the
ortic arch endovascularly are critical to a successful outcome.
Dr G. Wheatley (Phoenix, Ariz). Dr Roselli, I would like to
ompliment you on an excellent study and excellent presentation,
nd I would also like to compliment your colleagues and yourself
n moving this field forward.
I have two questions. The first is related to the number of
atients who underwent an open thoracoabdominal approach dur-
ng the same period of this study, just to get a sense of how many
atients were involved and whether or not the selection criteria
etermined who got in each study in terms of whether it was an
ndovascular requirement or were there other factors to determine
ho was selected?
My second question is, Could you elaborate a little bit more on
he intense imaging in terms of 3-D reconstruction and mapping?
think that is one important component to the success of this
rocedure.
Dr Roselli. Thanks, Grayson. I don’t know the exact number of
atients, but I believe we have done over 100 open thoracoab-
ominal aneurysm repairs during this period. And you are exactly
ight about the importance of 3-D imaging. I didn’t have time to
alk about the planning of these devices, but it is very intensive.
e do all the planning ourselves with the use of 3-D work stations,
nd it is important to be very facile with that. I should add that to
he answer to Dr Coselli’s second question.
Dr C. Miller (Stanford, Calif). Dr Roselli and his colleagues
ave shared with us some unbelievable technical wizardry today,
hich is most impressive. My question pertains to why an inter-
ention was deemed necessary in these very old and very sick
atients. Some of us who have been around awhile have learned
he hard way in dealing with patients with thoracoabdominal
neurysms that if you tamper with the work of the Lord too often,
ou are going to get caught occasionally and things will not go
ell. You didn’t tell us, Eric, or perhaps I missed it, what was the
linical indication mandating a procedure in these individuals who
re old and trying to die from so many other diseases? It appears
and Cardiovascular Surgery ● Volume 133, Number 6 1481
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A
CDo me more and more that in this country one can’t die with dignity
nymore.
Dr Roselli. All right. Thanks, Dr Miller. You are right, these
atients are sick and old; however, the indication for therapy in
hese patients was that they were at high risk from dying from their
neurysms. And as shown in the data, for the patients with type 1,
, and 3 aneurysms, the mean aneurysm size was nearly 8 cm. We
on’t treat every single high-risk patient with an intervention;
ome patients are selected to be treated medically, but I don’t have
he data on the medically treated patients to make a comparison.
Dr. Miller. My question had more to do with symptoms, not
ust size, justifying a prophylactic operation in an asymptomatic
ndividual. If these patients are symptomatic and presenting with
ain, then sure, one probably ought to intervene; conversely, in
symptomatic very elderly patients with a large thoracoabdominal s
482 The Journal of Thoracic and Cardiovascular Surgery ● Junneurysm who have multiple comorbidities and little quality of life
eft, I am not sure we should do anything except keep them
omfortable.
Dr. Roselli. Well, that is an interesting question, but we do
ave over 80% survival at 1 year in these folks with large aneu-
ysms and no late aneurysm-related deaths. To answer your ques-
ion, though, no, these patients were not symptomatic. Symptom-
tic patients, unfortunately, are not candidates for this approach
ecause there is an inherent delay in the design and construction of
he device.
Dr S. Mitchell (Stanford, Calif). Great presentation and bold
ork. The question, I may have missed it, were there any left
ubclavian arteries covered during these repairs?
Dr Roselli. There was 1, and that patient did have a carotidubclavian bypass beforehand.
e 2007
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ppendix E1: Definitions of Morbidity
eurologic injury included stroke and spinal cord injury and was
efined by typical findings on clinical exam and confirmation by
maging and consultation with a neurologist.
Myocardial infarction was determined by rise and fall in en-
ymes and associated characteristics.
Respiratory failure was defined as the need for mechanical
entilation after reintubation or tracheostomy.
Renal dysfunction was defined as a sustained increase in the
erum creatinine by 30% or more, loss of renal branch patency, or
he need for new onset of hemodialysis.
A
CDABLE E1. Complications following endovascular repair of
horacoabdominal aortic aneurysm
orbidity n  73 (%)
enal
Sustained creatinine elevation 6 (8.2)
Dialysis-dependent renal failure 1 (1.4)
Renal occlusion/stenosis 5 (6.8)
pinal cord injury 2 (2.7)
ype II or III TAA 2/28 (7.1)
espiratory failure 5 (6.8)
racheostomy 2 (2.7)
yocardial infarction 4 (5.5)
neurysm growth 0
upture 0
onversion 0
evice integrity
Component separation 0
Barb fracture 0
Stent fracture 1 (2.1)
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